Literature DB >> 29553945

Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway.

Tang Bufu1, Xu Di1, Zhao Yilin2, Liang Gege1, Chen Xi1, Wang Ling1.   

Abstract

Colorectal cancer (CRC) is one of the most frequent malignant tumors. Signaling by the PI3K/AKT pathway is crucial for CRC development and progression, including proliferation and migration. Celastrol has an anticancer effect, but its mechanism needs to be determined. Here, we showed that celastrol suppressed CRC cell proliferation and migration. Celastrol treatment also decreased the PI3K/AKT pathway components, and MMP3 and MMP7 expression levels. In addition, knockdown of AKT, not mTOR, inhibited MMP3 and MMP7 expression levels and AKT silencing promoted the celastrol-induced effects on CRC cell proliferation and migration. Taken together, these findings indicated that the celastrol-induced antitumor effects were mediated through MMP3 and MMP7 by the PI3K/AKT signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29553945     DOI: 10.1097/CAD.0000000000000621

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  14 in total

1.  Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer.

Authors:  Yanfeng Gao; Shuang Zhou; Lizhi Pang; Juechen Yang; Han John Li; Xiongwei Huo; Steven Y Qian
Journal:  Free Radic Res       Date:  2019-02-18

Review 2.  Evidence for Anticancer Effects of Chinese Medicine Monomers on Colorectal Cancer.

Authors:  Tian-Hao Guo; Yuan-Yuan Li; Sheng-Wei Hong; Qian-Yu Cao; Heng Chen; Yuan Xu; Guo-Liang Dai; Gang Shao
Journal:  Chin J Integr Med       Date:  2022-04-13       Impact factor: 2.626

3.  Potential mechanisms of action of celastrol against rheumatoid arthritis: Transcriptomic and proteomic analysis.

Authors:  Song Xinqiang; Dai Erqin; Zhang Yu; Du Hongtao; Wang Lei; Yang Ningning
Journal:  PLoS One       Date:  2020-07-29       Impact factor: 3.240

4.  miR-200a contributes to the migration of BMSCs induced by the secretions of E. faecalis via FOXJ1/NFκB/MMPs axis.

Authors:  Mingwei Li; Lifan Wei; Wei Zhou; Zhiyan He; Shujun Ran; Jingping Liang
Journal:  Stem Cell Res Ther       Date:  2020-07-25       Impact factor: 6.832

5.  A microfluidic chip-based co-culture of fibroblast-like synoviocytes with osteoblasts and osteoclasts to test bone erosion and drug evaluation.

Authors:  Hui-Peng Ma; Xue Deng; Deng-Yi Chen; Di Zhu; Jin-Ling Tong; Ting Zhao; Jin-Hui Ma; Yan-Qiu Liu
Journal:  R Soc Open Sci       Date:  2018-09-12       Impact factor: 2.963

6.  Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism.

Authors:  Bo Li; Junkai Zhang; Ya Su; Yiling Hou; Zhenguo Wang; Lin Zhao; Shengkai Sun; Hao Fu
Journal:  Mol Med Rep       Date:  2019-08-26       Impact factor: 2.952

7.  Matrix metalloproteinase 3 regulates angiotensin II‑induced myocardial fibrosis cell viability, migration and apoptosis.

Authors:  Jin Shu; Yiwen Gu; Li Jin; Haiya Wang
Journal:  Mol Med Rep       Date:  2020-12-20       Impact factor: 2.952

8.  Integrated whole transcriptome and small RNA analysis revealed multiple regulatory networks in colorectal cancer.

Authors:  Hibah Shaath; Salman M Toor; Mohamed Abu Nada; Eyad Elkord; Nehad M Alajez
Journal:  Sci Rep       Date:  2021-07-14       Impact factor: 4.379

9.  Celastrol inhibits colorectal cancer through TGF-β1/Smad signaling.

Authors:  Zhitao Jiang; Qianyu Cao; Guoliang Dai; Jianchun Wang; Chundi Liu; Lingyan Lv; Jinhuo Pan
Journal:  Onco Targets Ther       Date:  2019-01-09       Impact factor: 4.147

10.  Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer.

Authors:  Yangyu Zhang; Lili Qin; Xiaobo Ma; Yueqi Wang; Yanhua Wu; Jing Jiang
Journal:  Dis Markers       Date:  2020-09-14       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.